PCSK9抑制剂与白癜风风险:孟德尔随机化研究
本研究利用欧洲人群GWAS汇总数据,通过药物靶点孟德尔随机化分析探索降脂药物对白癜风风险的影响。结果显示遗传代理的PCSK9抑制与白癜风风险降低相关(OR=0.71,95%CI 0.52-0.95),并在两个独立生物库中重复验证。PCSK9及5种潜在蛋白介质可能成为白癜风治疗新靶点。
要点
- 遗传代理的PCSK9抑制与白癜风风险降低相关(OR=0.71)。
- PCSK9抑制的 protective 效应在两个独立生物库中重复验证。
- PCSK9及CCN5、CXCL12等蛋白介质可能为白癜风治疗新靶点。
核心结论
- PCSK9抑制剂可能降低白癜风风险,PCSK9及潜在蛋白介质是有前景的治疗靶点。
研究设计与样本
- 基于欧洲 ancestry 的GWAS汇总数据,采用降脂药物和蛋白抑制孟德尔随机化分析,并进行多变量和两步法MR识别介质。
- 数据来源包括全球脂质遗传学联盟的7种血脂谱及UK Biobank和deCODE两个大型生物库的4719种蛋白。
主要发现
- 降脂MR提示PCSK9在降低白癜风风险中可能起作用(OR=0.71,95%CI 0.52-0.95)。
- PCSK9抑制MR在UK Biobank中重复验证(OR=0.82,95%CI 0.71-0.96),在deCODE中重复验证(OR=0.78,95%CI 0.67-0.91)。
- 多变量MR提示已知血脂谱不介导PCSK9与白癜风的关系,两步法MR识别出5种潜在蛋白介质:CCN5、CXCL12、FCRL1、legumain和FGF2。
关键数值与推荐
- PCSK9抑制与白癜风风险降低相关,OR范围0.71-0.82(95%CI均低于1)。
临床怎么用
- PCSK9抑制剂可能作为白癜风治疗的候选药物,PCSK9及鉴定出的蛋白介质可作为新药开发靶点。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Lipid-lowering agents have been suggested as a therapeutic option for vitiligo on the basis of the potential pathogenic role of lipid metabolism abnormalities. We aimed to explore the impact of genetically proxied lipid-lowering agents on the risk of vitiligo and potentially associated mediators. GWAS summary statistics for European ancestry were extracted from the largest available meta-analysis for vitiligo: the Global Lipids Genetics Consortium for 7 lipid profiles and 2 large biobanks, UK Biobank and deCODE, for 4719 proteins. After identifying lipid-lowering agents with genetically proxied protective effects against vitiligo using lipid-lowering and protein-inhibition Mendelian randomization (MR) analyses, multivariable and 2-step MR analyses were conducted to identify potential mediators between lipid-lowering agents and vitiligo. Lipid-lowering MR indicated a potential role of PCSK9 in reducing the vitiligo risk (OR [95% confidence interval] = 0.71 [0.52-0.95]), which was replicated in PCSK9-inhibition MR analyses across 2 separate biobanks (UK Biobank: OR [95% confidence interval] = 0.82 [0.71-0.96]; deCODE: OR [95% confidence interval] = 0.78 [0.67-0.91]). Multivariable MR suggested that well-known lipid profiles do not mediate the relationship between PCSK9 and vitiligo, whereas 2-step MR analyses identified 5 potential protein mediators (CCN5, CXCL12, FCRL1, legumain, and FGF2). Hence, PCSK9 inhibitor may attenuate the vitiligo risk; PCSK9 and the potential protein mediators can serve as promising novel therapeutic targets for its effective treatment.
引用
- Kang TJ, Lee SY, Yoon S, et al. PCSK9 Inhibitors and the Risk of Vitiligo: A Mendelian Randomization Study. J Invest Dermatol. 2024. PMID: 39127093. doi:10.1016/j.jid.2024.07.021
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。